Compare TJX Companies Inc (TJX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TJX Companies Inc vs TransMedics Group Inc — how do they compare? TJX Companies Inc trades at $138.76 (market cap $152.62B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: TJX Companies Inc is far larger — about 55.7× TransMedics Group Inc's market cap, and TJX Companies Inc pays a 1.38% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TJX Companies Inc for 97 Days and TransMedics Group Inc for 24 Days on average.
| TJX | TMDX | |
|---|---|---|
Market Cap | $152.62B | $2.74B |
Volume | 8,079,794 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $168.41 | $150.42 |
52-Week Low | $122.84 | $61.99 |
Typical Hold Time | 97 Days | 24 Days |
Enterprise Value | $160.93B | $3.13B |
Dividend Yield | 1.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TJX trades at $138.76, down slightly by 0.03% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals, with revenue rising to $56.36B in 2025 and net income reaching $4.86B, alongside robust profitability metrics like a 62.17% ROE. Recent quarterly earnings have consistently beaten expectations, and the firm maintains a solid balance sheet with manageable debt levels.
The outlook for TJX is positive, supported by Wall Street's strong buy consensus (84.9% buy ratings) and a $174.15 price target implying 28% upside. Key risks include competitive pressures in off-price retail and sensitivity to consumer spending trends. Investor sentiment is buoyed by earnings momentum and expansion potential, though overbought technical conditions may prompt near-term volatility.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
